ClinicalTrials.gg
RecruitingNCT06509334Updated Nov 29, 2024

Trial of JYB1904 in Chronic Spontaneous Urticaria.

A Phase 2 interventional study of JYB1904 and JYB1904 in Chronic Spontaneous Urticaria, sponsored by Jemincare. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-29.

Sponsored by Jemincare · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Chronic Urticaria with a site in China — 16 open to participants now, 20 under way, 5 of them phase 3. Chronic Urticaria · China.

Planned enrollment
14th of 30
135 · median 110
Started
2024
with 6 others
Phase 2
7 of 34
6 open now
Primary completion
2026-07
later than 3 of 19 live
Registered
16th of 34
by date
Lead sponsor
2 of 34
Jemincare

Among the 34 studies in Chronic Urticaria with a site in China, this one is the 14th largest by planned enrollment of the 30 interventional ones that give a count, is one of 7 that started in 2024, is one of 7 in phase 2, reaches primary completion later than 3 of the 19 other live ones, and was the 16th registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

16 of the 34 studies in Chronic Urticaria with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Chronic Urticaria with a site in China, or all of them as a file.
02

Study summary

This Phase II Trial is Meant to Evaluate the Efficacy, Safety and Tolerability of JYB1904 Injection in Patients With Chronic Spontaneous Urticaria.

03

Conditions studied

  • Chronic Spontaneous Urticaria

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adult subjects (≥18 years of age).
  • Diagnosis of Chronic Spontaneous Urticaria(CSU) ≥ 3 months prior to Screening Visit 1 and previously inadequately controlled with a second-generation H1 antihistamine.
  • Itching and hives lasting ≥ 6 weeks prior to Screening Visit 1.
  • Have a UAS7 (range 0 - 42) ≥ 16, an ISS7 (range 0 - 21) ≥ 6, and an HSS7 (range 0 - 21) ≥ 6 within 7 days prior to randomization.

Exclusion criteria

Exclusion Criteria:

  • Induced urticaria with a defined trigger, including artificial urticaria (cutaneous scratches), cold-contact, heat-contact, solar, pressure, delayed-pressure, water-source, cholinergic, or contact urticaria
  • Any other dermatological condition with chronic itching, such as atopic dermatitis, herpetic pemphigoid, herpetic dermatitis, senile itching, or psoriasis, which in the opinion of the investigator may affect the study assessment and study results
  • Other conditions with symptoms of urticaria or angioedema, including but not limited to urticarial vasculitis, pigmented urticaria, erythema multiforme, mastocytosis, hereditary urticaria, or acquired/drug-induced urticaria.
  • Previous allergic reaction or poor efficacy with omalizumab.
  • or to antihistamines (e.g., fexofenadine, loratadine, desloratadine, cetirizine, levocetirizine, rupatadine, bilastine) or any of the ingredients.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
135 participants (estimated)

Study arms

  • Experimental
    JYB1904: Dose-1

    Drug: JYB1904

  • Experimental
    JYB1904: Dose-2

    Drug: JYB1904

  • Active comparator
    Omalizumab

    Drug: Omalizumab

Interventions

  • Participants will receive JYB1904 at week0 and receive placebo at week4,8,12

  • Participants will receive JYB1904 at week0,8 and receive placebo at week4,12

  • Participants will receive Omalizumab every 4 weeks for 12 weeks

06

What researchers measure

Primary outcomes

  1. Urticaria activity score used for 7 consecutive days(UAS7)

    Change from baseline in urticaria activity score used for 7 consecutive days (UAS7) at weeks 8, 12, and 16.Score 0-42, UAS7=0 for complete remission

    Time frame: Baseline through 16 weeks

Secondary outcomes

  1. Urticaria activity score used for 7 consecutive days(UAS7)

    Change from baseline in UAS7 at weeks 4, 24 and 32.Score 0-42, UAS7=0 for complete remission

    Time frame: Baseline through 32 weeks

  2. Itch severity score used for 7 consecutive days(ISS7)

    Change from baseline in itch severity score used for 7 consecutive days(ISS7) at weeks 4, 8, 12, 16, 24 and 32.Score 0-21, ISS7=0 for complete remission of itch

    Time frame: Baseline through 32 weeks

  3. Hive severity score used for 7 consecutive days (HSS7)

    Change from baseline in hive severity score used for 7 consecutive days(HSS7) at weeks 4, 8, 12, 16, 24, 32.Score 0-21, HSS7=0 for complete remission of hives

    Time frame: Baseline through 32 weeks

  4. Angioedema activity score used for 7 consecutive days(AAS7)

    Change from baseline in angioedema activity score used for 7 consecutive days(AAS7) at weeks 4, 8, 12, 16, 24, 32.Score 0-105, higher scores mean a worse outcome

    Time frame: Baseline through 32 weeks

  5. Urticaria activity score used for 7 consecutive days(UAS7)

    Proportion of subjects with UAS7=0 at weeks 4, 8, 12, 16, 24, 32.Score 0-42, UAS7=0 for complete remission

    Time frame: Baseline through 32 weeks

  6. Dermatology Life Quality Index(DLQI)

    Change from baseline in Dermatological Life Quality Index (DLQI) at weeks 4, 8, 12, 16, 24 and 32.Score 0-30, higher scores mean a worse outcome

    Time frame: Baseline through 32 weeks

  7. Safety and tolerability

    Adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Baseline through 32 weeks

  8. Trends in serum total immunoglobulin E(IgE)

    Serum total IgE levels at weeks 4, 8, 12, 16, 24 and 32

    Time frame: Baseline through 32 weeks

  9. Positive detection rate of anti-drug antibody (ADA)

    ADA positive detection rate at 32 weeks

    Time frame: Baseline through 32 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jul 2026, 23 months after the start.

Of 31 phase 2 interventional studies under Chronic Urticaria, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's planned 23 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2024
First posted
Jul 19, 2024
StartActual
Aug 4, 2024
Primary completionEst.
Jul 15, 2026
CompletionEst.
Jul 15, 2026
Last update
Nov 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06509334
Lead sponsor
Jemincare
Responsible party
Sponsor
First posted
Jul 19, 2024
Start date
Aug 4, 2024
Primary completion
Jul 15, 2026 (estimated)
Completion
Jul 15, 2026 (estimated)
Last update
Nov 29, 2024

Study contacts

Yila Sha
Contact
shayila@jemincare.com
86-021-52887926

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ozureprubart

Start the discussion